Team:NTNU-Trondheim

From 2013.igem.org

(Difference between revisions)
 
(22 intermediate revisions not shown)
Line 19: Line 19:
-
<div id="top-section3"><center><img src="https://static.igem.org/mediawiki/2013/5/55/Logo-ntnu.png" alt="header" border="0"  usemap="#igemmap" width="1000" height="400"></center></div>
+
<div id="top-section3"><center><img src="https://static.igem.org/mediawiki/2013/2/21/Logo2_NTNU.png" alt="header" border="0"  usemap="#igemmap" width="1000" height="400"></center></div>
Line 33: Line 33:
<div id='cssmenu'>
<div id='cssmenu'>
<ul>
<ul>
-
   <li class='active'><a href='https://2013.igem.org/Team:NTNU-Trondheim'><span>Home</span></a></li>
+
   <li><a href='https://2013.igem.org/Team:NTNU-Trondheim'><span>Home</span></a></li>
   <li class='has-sub'><a href='#'><span>Project</span></a>
   <li class='has-sub'><a href='#'><span>Project</span></a>
       <ul>
       <ul>
         <li><a href='https://2013.igem.org/Team:NTNU-Trondheim/Project'><span>Project description</span></a></li>
         <li><a href='https://2013.igem.org/Team:NTNU-Trondheim/Project'><span>Project description</span></a></li>
 +
        <li><a href='https://2013.igem.org/Team:NTNU-Trondheim/novelapproach'><span>A novel approach</span></a></li>
         <li><a href='https://2013.igem.org/Team:NTNU-Trondheim/Model'><span>Modelling</span></a></li>
         <li><a href='https://2013.igem.org/Team:NTNU-Trondheim/Model'><span>Modelling</span></a></li>
         <li><a href='https://2013.igem.org/Team:NTNU-Trondheim/Experiments_and_Results'><span>Experiments and Results</span></a></li>
         <li><a href='https://2013.igem.org/Team:NTNU-Trondheim/Experiments_and_Results'><span>Experiments and Results</span></a></li>
         <li><a href='https://2013.igem.org/Team:NTNU-Trondheim/Parts'><span>BioBrick Parts</span></a></li>
         <li><a href='https://2013.igem.org/Team:NTNU-Trondheim/Parts'><span>BioBrick Parts</span></a></li>
-
         <li class='last'><a href='https://2013.igem.org/Team:NTNU_Trondheim/Attributions'><span>Attributions</span></a></li>
+
         <li class='last'><a href='https://2013.igem.org/Team:NTNU-Trondheim/Acknowledgements'><span>Acknowledgements</span></a></li>
       </ul>
       </ul>
   </li>
   </li>
Line 79: Line 80:
<div class="row">
<div class="row">
-
<div class="col6" align = "justify">
+
<div class="col12-3" align = "justify">
-
<div class="col6" align = "justify" style="background-color:#C3A7F3;>
+
<div class="col12-3" align = "justify" style="background-color:#C3A7F3;>
<p style="text-align:center; color:black; "><b> The project</b> </p> </div>
<p style="text-align:center; color:black; "><b> The project</b> </p> </div>
<br><br>
<br><br>
-
<p>Gram negative bacteria export numerous proteins into the periplasm. The twin-arginine translocation pathway (Tat pathway) is a protein export, or secretion pathway found in plants, bacteria, and archaea.
+
<p>All gram negative bacteria produce outer membrane vesicles (OMVs) by bulging of from their outer membrane. These OMVs contain different proteins and carry out varies functions such as quorum sensing, involvement in pathogenesis and transporting enzymes to distal locations. In our project we wish to prove that OMVs can be manipulated and to thereby implicate OMVs potential as a drug delivery vehicle. This is an innovative and <a href="https://2013.igem.org/Team:NTNU-Trondheim/novelapproach"> novel approach </a>to create a safe way to deliver drugs in the body. <br><br>
-
The Tat pathway serves to actively translocate folded proteins across a lipid membrane bilayer. By using this transportationsystem we aim to introduce new proteins into the periplasm of bacteria. Once in the periplasm the protein will to some extent end up in outer membrane vesicles (OMV's) that budd of the bacteria.<br><br>
+
-
As all gram negative bacteria produce outer membrane vesicles, we looked into the content of these vesicles. Was the sorting of proteins random? Could we direct certain proteins toward them? And what function would that give? Can we use this to our advantage?<br><br>
+
We are going to prove that the OMVs can be manipulated by introducing two different proteins. The first one is a fusion protein of GFP and RFP. This will make it possible to visualize the vesicles as well as investigating the new functionalities of fusing two fluorescent proteins together. The second protein we wish to introduce to the vesicles is the transmembrane protein G derived from <i> Streptococcus dysgalactiae ssp. equisimilisi</i>. Protein G is known to bind to Human Serum Albumin (HSA) which helps <i>S.dysgalactiae subsp. equisimilis</i> hide from the immune system. Protein G will therefore be a potential important piece in a drug carrier by masking it from immunological destruction and making it stable in the blood stream. <br><br>
-
Studies show that a twin-arginine signal peptide is able to direct the export of active green fluorescent protein (GFP) in E.coli and that translocation almost exclusively occur by the Tat-pathway. With this in mind we proceeded with making a construct containing tat and a GFP.
+
In order to direct the proteins into the periplasm and vesicles they need to have a tat signal peptide at the N-terminal. This will transport the proteins through twin-arginine translocation pathway (Tat pathway). Studies show that a twin-arginine signal peptide is able to direct the export of active green fluorescent protein (GFP) in <i> Escherichia coli </i>. We also wish to be able to regulate the production and thereby the export of proteins to OMVs. In order to accomplish this task we will set the gene constructs under regulation of the Pm/Xyls promotor system. This is a positive regulation system that is activated by the inducer m-toluic acid<br><br>
-
As the goal of the project is to determine if vesicles can be utilized for drug delivery we want to see if they can be masked from the immunesystem by introducing a specific protein.<br><br>
+
-
Protein G is known to bind to Human Serum Albumin which helps S.dysgalactiae subsp. equisimilis hide from the immune system. Protein G could therefore be a potential important piece in a drug carrier by masking it from immunological destruction. Introducing protein G into vesicles also demonstrate that it is indeed possible to manipulate the content and therefore the properties of OMV's. <br>
+
Introducing these proteins into vesicles also demonstrate that it is indeed possible to manipulate the content and therefore the properties of OMV's. We will prove the concept that OMVs can be engineered to meet the criteria of a drug delivery vehicle. <br><br>
  </p>
  </p>
<div class ="row-end"> </div>
<div class ="row-end"> </div>
 +
</div>
 +
<div class="row">
 +
<div class="col12-3" align = "justify">
 +
<p><a href="https://2013.igem.org/Team:NTNU-Trondheim/Achievements">Achievements</a><br>
 +
<a href="https://2013.igem.org/Team:NTNU-Trondheim/Achievements">Medal criteria</a><br></p>
 +
<div class="row-end"> </div>
</div>
</div>
Line 103: Line 108:
<div class="row">
<div class="row">
-
<div class="col4" style="background-color:#C3A7F3;><a href="https://2013.igem.org/Team:NTNU-Trondheim/Project#Vesicles"> <img src="https://static.igem.org/mediawiki/2013/b/b2/Marialab.jpg" div class="circular" width="303">
+
<div class="col4" style="background-color:#C3A7F3;><a href="https://2013.igem.org/Team:NTNU-Trondheim/Project">  
-
  <p style="text-align:center; color:black; "> <b>Vesicle project</b> </p> </div>
+
<img src="https://static.igem.org/mediawiki/2013/3/34/Immunecell_vesicles.png" div class="circular" width="303"></a>
 +
  <p style="text-align:center; color:black; "> <b><a href="https://2013.igem.org/Team:NTNU-Trondheim/Project">Vesicle project</a></b> </p> </div>
-
<div class="col4"style="background-color:#C3A7F3;> <a href="https://2011.igem.org/Team:Berkeley/Project#ToxRChimera"><img src="https://static.igem.org/mediawiki/2013/e/e4/FP_dimer.png" div class="circular" width="200"> </a>
+
<div class="col4" style="background-color:#C3A7F3;> <a href="https://2013.igem.org/Team:NTNU-Trondheim/Project">
-
<p style="text-align:center; color:black;"> <b>Fluorescence protein dimers</b> </p></div>
+
<img src="https://static.igem.org/mediawiki/2013/a/a0/GFP_PERIPLASM.png" div class="circular" width="200"> </a>
 +
<p style="text-align:center; color:black;"> <b><a href="https://2013.igem.org/Team:NTNU-Trondheim/Project">Fluorescence protein dimers</a></b> </p></div>
-
<div class="col4" style="background-color:#C3A7F3"><a href="https://2011.igem.org/Team:Berkeley/Project#StressPromoters"><img src="https://static.igem.org/mediawiki/2011/2/2b/Subtitlepic2header.jpg" div class="circular"
+
<div class="col4" style="background-color:#C3A7F3;><a href="https://2013.igem.org/Team:NTNU-Trondheim/Project">
-
onmouseover="this.src='https://static.igem.org/mediawiki/2011/3/32/Subtitlepic2headerhover.jpg'"
+
<img src="https://static.igem.org/mediawiki/2013/d/d1/Modelpic.jpg" div class="circular" width="230"></a>
-
onmouseout="this.src='https://static.igem.org/mediawiki/2011/2/2b/Subtitlepic2header.jpg'" width="230"></a>
+
<p style="text-align:center; color:black;"><b><a href="https://2013.igem.org/Team:NTNU-Trondheim/Project"> Pm/XylS promoter</a></b> </p> </div>
-
<p style="text-align:center; color:black;"><b> PmXylS promoter</b> </p> </div>
+
<div class ="row-end"> </div>
<div class ="row-end"> </div>
</div>
</div>
Line 126: Line 132:
<div class="col4" style="background-color:#C3A7F3;>
<div class="col4" style="background-color:#C3A7F3;>
<p style="text-align:center; color:black; "> <b> About us</b></p> </div>
<p style="text-align:center; color:black; "> <b> About us</b></p> </div>
-
<p>This is the third year a team from the Norwegian University of Science and Technology (NTNU) is participating in the iGEM competition. Our team consists of five students with background in Biotechnology, Molecular Medicine and Medical Technology. Mostly our collective background is in molecular biology colored with biophysics, immunology and biotechnology. We have four advisors with different specialities! Rahmi is our lab-GOD and has all the answers. Eivind gives us money and inspiration, Martin is our GFP-expert and Gunvor with her past iGEM team experience has been a lot of help! We are naive students that want to come up with crazy ideas that supervisors are to experienced to consider an opportunity. Our project this year is HIGH-risk and it was almost immediately clear to us that this was what we wanted to do this year. Considering the time-limit of iGEM it was an ambitious project and had everything gone as planned and expected we could have reached our goal. We still believe the project has potential and should not be abandoned. We'we all enjoyed working as a team and learned tons about synthetic biology and the potential this field has feels unlimited! We have had a lot of fun, the life of a scientist is like a rollercoaster of up's and down's but the excitement and curiosity of research will always be a strong motivator!</p>
+
<p>This is the third year a team from the Norwegian University of Science and Technology (NTNU) is participating in the iGEM competition. Our team consists of five students with background in Biotechnology, Molecular Medicine and Medical Technology. Mostly our collective background is in molecular biology colored with biophysics, immunology and biotechnology. We have four advisors with different specialities! Rahmi is our lab-GOD and has all the answers. Eivind gives us money and inspiration, Martin is our GFP-expert and Gunvor with her past iGEM team experience has been a lot of help! We are naive students that want to come up with crazy ideas that supervisors are to experienced to consider an opportunity. Our project this year is HIGH-risk and it was almost immediately clear to us that this was what we wanted to do this year. Considering the time-limit of iGEM it was an ambitious project and had everything gone as planned and expected we could have reached our goal. We believe the project has potential and it should be further investigated. We've all enjoyed working as a team and learned tons about synthetic biology and the potential this field has feels unlimited! We have had a lot of fun, the life of a scientist is like a rollercoaster of ups and downs but the excitement and curiosity of research will always be a strong motivator!</p>
</div>
</div>
Line 139: Line 145:
             <div class="ribbon"></div>
             <div class="ribbon"></div>
             <div id="slider" class="nivoSlider">
             <div id="slider" class="nivoSlider">
-
                 <img src="https://static.igem.org/mediawiki/2011/2/2c/Slideshow6.jpg" />
+
                 <img src="https://static.igem.org/mediawiki/2013/c/c6/Slidentnu1.JPG" />
-
                 <img src="https://static.igem.org/mediawiki/2011/f/f5/Slideshow7.jpg" />
+
                 <img src="https://static.igem.org/mediawiki/2013/5/52/Slidentnu2.JPG" />
-
                 <img src="https://static.igem.org/mediawiki/2011/b/b5/Slideshow14.jpg" />
+
                 <img src="https://static.igem.org/mediawiki/2013/c/cc/Slidentnu3.JPG" />
-
                 <img src="https://static.igem.org/mediawiki/2011/7/71/Slideshow15.jpg" />
+
                 <img src="https://static.igem.org/mediawiki/2013/7/7f/Slidentnu5.JPG" />
-
                 <img src="https://static.igem.org/mediawiki/2011/1/1a/Slideshow14.JPG" />
+
                 <img src="https://static.igem.org/mediawiki/2013/2/2f/Slidentnu6.JPG" />
-
                 <img src="https://static.igem.org/mediawiki/2011/b/b2/Slideshow10.jpg" />
+
                 <img src="https://static.igem.org/mediawiki/2013/c/cc/Slidentnu7.jpg" />
-
                 <img src="https://static.igem.org/mediawiki/2011/2/28/Slideshow12.jpg" />
+
                 <img src="https://static.igem.org/mediawiki/2013/2/25/Slidentnu8.JPG" />
-
                 <img src="https://static.igem.org/mediawiki/2011/9/9b/Slideshow13.jpg" />
+
                 <img src="https://static.igem.org/mediawiki/2013/2/2f/Slidentnu9.JPG" />
-
                 <img src="https://static.igem.org/mediawiki/2011/9/94/Slideshow11.jpg" />
+
                 <img src="https://static.igem.org/mediawiki/2013/4/4f/Slidentnu10.JPG" />
 +
                <img src="https://static.igem.org/mediawiki/2013/9/95/Slidentnu11.JPG" />
 +
                <img src="https://static.igem.org/mediawiki/2013/2/25/Slidentnu12.JPG" />
 +
                <img src="https://static.igem.org/mediawiki/2013/4/4f/Slidentnu13.JPG" />
             </div>
             </div>
     </div>
     </div>

Latest revision as of 22:50, 4 October 2013

Trondheim iGEM 2013

header
Mercury
The project



All gram negative bacteria produce outer membrane vesicles (OMVs) by bulging of from their outer membrane. These OMVs contain different proteins and carry out varies functions such as quorum sensing, involvement in pathogenesis and transporting enzymes to distal locations. In our project we wish to prove that OMVs can be manipulated and to thereby implicate OMVs potential as a drug delivery vehicle. This is an innovative and novel approach to create a safe way to deliver drugs in the body.

We are going to prove that the OMVs can be manipulated by introducing two different proteins. The first one is a fusion protein of GFP and RFP. This will make it possible to visualize the vesicles as well as investigating the new functionalities of fusing two fluorescent proteins together. The second protein we wish to introduce to the vesicles is the transmembrane protein G derived from Streptococcus dysgalactiae ssp. equisimilisi. Protein G is known to bind to Human Serum Albumin (HSA) which helps S.dysgalactiae subsp. equisimilis hide from the immune system. Protein G will therefore be a potential important piece in a drug carrier by masking it from immunological destruction and making it stable in the blood stream.

In order to direct the proteins into the periplasm and vesicles they need to have a tat signal peptide at the N-terminal. This will transport the proteins through twin-arginine translocation pathway (Tat pathway). Studies show that a twin-arginine signal peptide is able to direct the export of active green fluorescent protein (GFP) in Escherichia coli . We also wish to be able to regulate the production and thereby the export of proteins to OMVs. In order to accomplish this task we will set the gene constructs under regulation of the Pm/Xyls promotor system. This is a positive regulation system that is activated by the inducer m-toluic acid

Introducing these proteins into vesicles also demonstrate that it is indeed possible to manipulate the content and therefore the properties of OMV's. We will prove the concept that OMVs can be engineered to meet the criteria of a drug delivery vehicle.


About us

This is the third year a team from the Norwegian University of Science and Technology (NTNU) is participating in the iGEM competition. Our team consists of five students with background in Biotechnology, Molecular Medicine and Medical Technology. Mostly our collective background is in molecular biology colored with biophysics, immunology and biotechnology. We have four advisors with different specialities! Rahmi is our lab-GOD and has all the answers. Eivind gives us money and inspiration, Martin is our GFP-expert and Gunvor with her past iGEM team experience has been a lot of help! We are naive students that want to come up with crazy ideas that supervisors are to experienced to consider an opportunity. Our project this year is HIGH-risk and it was almost immediately clear to us that this was what we wanted to do this year. Considering the time-limit of iGEM it was an ambitious project and had everything gone as planned and expected we could have reached our goal. We believe the project has potential and it should be further investigated. We've all enjoyed working as a team and learned tons about synthetic biology and the potential this field has feels unlimited! We have had a lot of fun, the life of a scientist is like a rollercoaster of ups and downs but the excitement and curiosity of research will always be a strong motivator!